Pristine Capital chairman responds to Labour’s Autumn budget. Watch the interview here.

Less Ads, More Data, More Tools Register for FREE
Sponsored Content
Sponsored Content

Pin to quick picksVerici Dx Regulatory News (VRCI)

Share Price Information for Verici Dx (VRCI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.50
Bid: 3.25
Ask: 3.75
Change: 0.00 (0.00%)
Spread: 0.50 (15.385%)
Open: 3.50
High: 3.50
Low: 3.50
Prev. Close: 3.50

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Lease signed for laboratory

29 Apr 2021 07:00

RNS Number : 9877W
Verici Dx PLC
29 April 2021
 

Verici Dx plc

("Verici Dx" or the "Company") 

 

Lease signed for laboratory as part of CLIA approval acceleration strategy

 

Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces it has signed the lease for the premises intended to be the CLIA1-certified laboratory, situated at the Innovation Park2 in Franklin, Tennessee, US, which is within the Palmetto region for CMS Medicare governance. Palmetto GBA, LLC is one of the largest Medicare administration contractors in the US.

 

In January 2021, the Company appointed David Schultenover to accelerate the CLIA approval process to enable faster commercial launch of Verici Dx's lead products, ClaravaTM and TutevaTM and setting up these premises is the first step in that accelerated pathway. The Company requires a CLIA-certified laboratory to be able to offer their diagnostic products to clinicians as a laboratory developed test (LDT) and approvals are expected by the end of the year. The Center for Medicare and Medicaid Services (CMS) regulates laboratory testing in the US through the CLIA regime, which requires all clinical laboratories to be certified before they can accept human samples for diagnostic testing.

 

David Schultenover, VP Quality and Regulatory Affairs at Verici Dx, commented: "I joined the Company in January this year to help expedite the CLIA approval strategy and signing the lease to this space marks the first step towards achieving these CLIA approvals necessary for commercial launch of the Company's leading products, ClaravaTM and TutevaTM. Innovation Park is an ideal location for the Company to establish operations and we are delighted with the quality of the premises which are well suited for our needs." 

 

1 - CLIA - Clinical Laboratory Improvement Amendments

2 - Innovation Park is a 10 acre campus for growing start-ups or established companies. More information can be found here: http://www.theinnovationpark.com/#campus 

 

Enquiries:

 

Verici Dx

www.vericidx.com

Sara Barrington, CEO 

Via Walbrook PR

Julian Baines, Chairman

 

 

N+1 Singer (Nominated Adviser & Broker)

Tel: 020 7496 3000

Aubrey Powell / Justin McKeegan / Tom Salvesen

 

 

Walbrook PR Limited

Tel: 020 7933 8780 or vericidx@walbrookpr.com

Paul McManus / Sam Allen

Mob: 07980 541 893 / 077502 558 258

 

 

 

About Verici Dx plc www.vericidx.com

Verici Dx is developing and commercialising tests to understand how a patient will and is responding to organ transplant, with an initial focus on kidney transplants. The body's own immune system poses a threat to a successful transplant or graft. Patients' immune systems differ in how they respond to the presence of the transplanted organ, characterising this response is called immune phenotyping. Our products and solutions are underpinned by extensive scientific research into the recipient's immune phenotype and how that impacts on acute rejection, chronic injury and ultimately failure of the transplant. These immuno-profile signatures also inform clinicians as to the optimal strategy for immunosuppressive and other therapies for the most successful treatment to ensure graft acceptance with the least amount of side effects.

 

The foundational research was driven by a deep understanding of cell-mediated immunity and is enabled by access to expertly curated collaborative studies in highly informative cohorts in kidney transplant.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAUWSKRAKUSUAR
Date   Source Headline
11th Oct 20247:00 amRNSUpdate on Local Coverage Determination and Trading
31st Jul 20247:00 amRNSLaunch of PTRA Assay using Verici Dx's technology
15th Jul 20247:00 amRNSHalf-year Report
11th Jul 20242:00 pmRNSNotice of Results and Business Update
1st Jul 20247:00 amRNSSignificant milestone re Thermo Fisher agreement
25th Jun 20241:27 pmRNSResult of AGM
18th Jun 20247:00 amRNSTransfer of urine samples to Thermo Fisher
31st May 20241:57 pmRNSNotice of AGM and posting of Annual Report
31st May 202410:00 amRNSLaunch of patient-focused educational tool
30th May 20247:00 amRNS2023 Annual Results
24th May 20247:00 amRNSNew data to be presented at ATC
27th Feb 20244:08 pmRNSHolding(s) in Company
22nd Feb 20247:00 amRNSHolding(s) in Company
21st Feb 20244:53 pmRNSHolding(s) in Company
21st Feb 20247:00 amRNSHolding(s) in Company
19th Feb 202412:35 pmRNSResult of General Meeting
14th Feb 20247:00 amRNSResult of Retail Offer
31st Jan 20247:00 amRNSVerici Dx announces new research initiative
26th Jan 202412:32 pmRNSPublication of Circular
25th Jan 202411:00 amRNSLaunch of Retail Offer
24th Jan 20246:11 pmRNSResult of Placing
24th Jan 202410:39 amRNSClose of Accelerated Bookbuild
24th Jan 20247:00 amRNSProposed Fundraising
8th Jan 20247:00 amRNSCAP accreditation
8th Jan 20247:00 amRNSMedicare National Payment Rate Confirmation
11th Dec 20237:00 amRNSTutiviaâ„¢ validation study published in Journal
29th Nov 20237:00 amRNSISO 27001 Information Security Certification
20th Nov 20237:00 amRNSInvestor Presentation
15th Nov 20237:00 amRNSCommercialisation agreement with Thermo Fisher
2nd Nov 20237:00 amRNSClaravaâ„¢ poster to be presented at ASN Kidney Week
29th Sep 20237:00 amRNSHalf-year Report
20th Jul 20237:00 amRNSCLIA Certificate of Compliance update
6th Jul 20237:00 amRNSInvestor Presentation
3rd Jul 20237:00 amRNSSuccessful clinical validation of Clarava™
29th Jun 20234:57 pmRNSResult of AGM
6th Jun 20237:00 amRNSNotice of AGM and posting of Annual Report
5th Jun 20237:01 amRNS2022 Annual Results
5th Jun 20237:00 amRNSProposed US pricing for Tutivia™
31st May 20237:00 amRNSNotice of Results
24th May 20237:01 amRNSUpdate re. EKF distribution of shares in Verici Dx
24th May 20237:00 amRNSDistribution of shares in Verici Dx plc
24th Apr 20237:00 amRNSFinal results timing
28th Mar 202311:05 amRNSSecond Price Monitoring Extn
28th Mar 202311:00 amRNSPrice Monitoring Extension
28th Mar 20239:05 amRNSSecond Price Monitoring Extn
28th Mar 20239:00 amRNSPrice Monitoring Extension
27th Mar 20234:35 pmRNSPrice Monitoring Extension
27th Mar 202311:05 amRNSSecond Price Monitoring Extn
27th Mar 202311:00 amRNSPrice Monitoring Extension
22nd Mar 20237:00 amRNSOperational Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Free Investment Tools

Register for FREE

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.